Albireo Pharma (ALBO) Received its Third Buy in a Row

After Wedbush and Jefferies gave Albireo Pharma (NASDAQ: ALBO) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Ed Arce maintained a Buy rating on Albireo Pharma today and set a price target of $80.00. The company’s shares closed last Wednesday at $26.88.

According to, Arce is a 5-star analyst with an average return of 13.2% and a 39.6% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Aurinia Pharmaceuticals, and Galmed Pharmaceuticals.

Currently, the analyst consensus on Albireo Pharma is a Strong Buy with an average price target of $77.00, which is a 180.4% upside from current levels. In a report released yesterday, Jefferies also maintained a Buy rating on the stock with a $72.00 price target.

See the top stocks recommended by analysts >>

Based on Albireo Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $3.66 million and net profit of $57.09 million. In comparison, last year the company earned revenue of $2.13 million and had a GAAP net loss of $30.74 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Albireo Pharma, Inc. is a pharmaceutical company, which engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its product pipeline includes A4250, Elobixibat, and A3384. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

Read More on ALBO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More